Literature DB >> 22017348

Maximizing the accuracy of Inferior petrosal sinus sampling: validation of the use of Prolactin as a marker of pituitary venous effluent in the diagnosis of Cushing's disease.

Paul Grant1, Dorota Dworakowska, Paul Carroll.   

Abstract

OBJECTIVE: This study aimed to increase the accuracy of the inferior petrosal sinus sampling (IPSS) procedure and reduce the false-negative rate through the addition of prolactin as a marker of pituitary venous outflow as well as validate this adjunct to the test process. CONTEXT: Inferior petrosal sinus sampling (IPSS) for ACTH is the current gold standard test for the differentiation of pituitary Cushing's disease from the ectopic ACTH syndrome. Although early studies with IPSS reported a diagnostic sensitivity and specificity approaching 100%, additional experience has revealed a false-negative rate of 1-10%. This has been attributed to either technical problems with unsuccessful petrosal sinus catheterization or anomalous venous drainage of the pituitary. Previous studies have suggested that the measurement of other anterior pituitary hormones may be useful during IPSS as a guide to the effectiveness of cannulation and to improve the diagnostic accuracy of the procedure.
DESIGN: We reviewed the data, in this retrospective cohort study, for all patients who had undergone IPSS for the investigation of ACTH-dependent hypercortisolism. PATIENTS: The study included 83 patients who underwent IPSS at St. Thomas's hospital between 2005 and 2010. MEASUREMENTS: Plasma ACTH and prolactin levels were measured both centrally and peripherally. The normalized ACTH/Prolactin inferior petrosal sinus/peripheral ratio was then calculated to assess the accuracy of the sampling procedure.
RESULTS: A total of 83 patients with confirmed ACTH-dependent cortisol excess underwent investigation with IPSS during the study period. Sixty-seven patients initially had a positive IPSS result (i.e. a basal central/peripheral ACTH ratio >2·0 and >3·0 post-CRH). However, when the concurrent prolactin data were used, six patients were additionally found to have positive results suggestive of pituitary Cushing's. The Prolactin normalized ACTH IPS/Peripheral ratios were all >0·8 in patients with proven Cushing's disease, whereas they were all <0·6 in proven ectopic ACTH syndrome. The diagnosis was subsequently confirmed histologically in 72 of the patients.
CONCLUSIONS: Using Prolactin as a concurrent index of pituitary venous effluent helps us recognize whether pituitary venous blood has been accurately sampled. Normalizing the IPS/peripheral ratios with Prolactin helps to improve the accuracy of the result and reduces the false-negative rate. With regards to the usefulness/validity of this test in clinical practice, it is relevant, reproducible and is easily adaptable from the existing diagnostic sequence.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22017348     DOI: 10.1111/j.1365-2265.2011.04257.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Is prolactin measurement of value during inferior petrosal sinus sampling in patients with adrenocorticotropic hormone-dependent Cushing's Syndrome?

Authors:  S T Sharma; L K Nieman
Journal:  J Endocrinol Invest       Date:  2013-07-26       Impact factor: 4.256

2.  Bilateral inferior petrosal sinus sampling in adrenocorticotropin-dependent hypercortisolism: always, never, or sometimes?

Authors:  M Losa; A Allora; P Panni; C Righi; P Mortini
Journal:  J Endocrinol Invest       Date:  2019-01-11       Impact factor: 4.256

3.  An algorithm to improve lateralization accuracy of inferior petrosal sinus sampling: procedural nuances for complex patterns of venous drainage. Patient series.

Authors:  Abhijith V Matur; Alaina M Body; Mark D Johnson; Matthew S Smith; Ruchi Bhabhra; Emily J Lester; Trisha L Stahl; Aaron W Grossman; Peyman Shirani; Jonathan A Forbes; Charles J Prestigiacomo
Journal:  J Neurosurg Case Lessons       Date:  2021-09-27

4.  Lateralization of inferior petrosal sinus sampling in Cushing's disease correlates with cavernous sinus venous drainage patterns, but not tumor lateralization.

Authors:  Mohammad Ghorbani; Hamideh Akbari; Christoph J Griessenauer; Christoph Wipplinger; Alireza Dastmalchi; Mojtaba Malek; Iraj Heydari; Reza Mollahoseini; Mohammad E Khamseh
Journal:  Heliyon       Date:  2020-10-22

5.  The value of prolactin in inferior petrosal sinus sampling with desmopressin stimulation in Cushing's disease.

Authors:  Xiaona Qiao; Hongying Ye; Xiaolong Zhang; Weiwei Zhao; Shuo Zhang; Bin Lu; Xuanchun Wang; Zhaoyun Zhang; Xi Wu; Min He; Xiaolong Zhao; Shiqi Li; Linuo Zhou; Yehong Yang; Renming Hu; Yiming Li
Journal:  Endocrine       Date:  2014-07-17       Impact factor: 3.633

6.  The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease.

Authors:  Joshua J Wind; Russell R Lonser; Lynnette K Nieman; Hetty L DeVroom; Richard Chang; Edward H Oldfield
Journal:  J Clin Endocrinol Metab       Date:  2013-04-03       Impact factor: 5.958

Review 7.  Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review.

Authors:  Jordan E Perlman; Philip C Johnston; Ferdinand Hui; Guy Mulligan; Robert J Weil; Pablo F Recinos; Divya Yogi-Morren; Roberto Salvatori; Debraj Mukherjee; Gary Gallia; Laurence Kennedy; Amir H Hamrahian
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

Review 8.  Bilateral inferior petrosal sinus sampling.

Authors:  Benedetta Zampetti; Erika Grossrubatscher; Paolo Dalino Ciaramella; Edoardo Boccardi; Paola Loli
Journal:  Endocr Connect       Date:  2016-06-27       Impact factor: 3.335

9.  Differential diagnostic value of bilateral inferior Petrosal sinus sampling (BIPSS) in ACTH-dependent Cushing syndrome: a systematic review and Meta-analysis.

Authors:  Hao Wang; Ying Ba; Qian Xing; Run-Ce Cai
Journal:  BMC Endocr Disord       Date:  2020-09-17       Impact factor: 2.763

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.